Bristol-Myers Squibb (NYSE: BMY), often referred to as BMS, is a pharmaceutical company, headquartered in New York City. The company was formed in 1989, following the merger of its predecessors Bristol-Myers and the Squibb Corporation. Squibb was founded in 1858 by Edward Robinson Squibb in Brooklyn, New York, while Bristol-Myers was founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, New York (both were graduates of Hamilton College).
Lamberto Andreotti became the company's CEO on May 4, 2010. Former CEO James M. Cornelius remains chairman of the Board of Directors.
Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Its mission is to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases."
BMS' primary R&D sites are located in Princeton, New Jersey (formerly Squibb) and Wallingford, Connecticut (formerly Bristol-Myers), with other sites in Hopewell and New Brunswick, New Jersey, and in Braine-l'Alleud, Belgium, and Tokyo.
A major restructuring involves focusing on the pharmaceutical business and biologic products along with productivity initiatives and cost-cutting and streamlining business operations through a multi-year program of on-going layoffs. As another cost-cutting measure Bristol-Myers also reduced subsidies for health-care to retirees and plans to freeze their pension plan at the end of 2009.[citation needed]
In November 2009, Bristol-Myers Squibb announced that it was "splitting off" Mead Johnson Nutrition by offering BMY shareholders the opportunity to exchange their stock for shares in Mead Johnson. According to Bristol-Myers Squibb, this move is expected to further sharpen the company's focus on biopharmaceuticals.
In 1999, President Clinton awarded Bristol-Myers Squibb the National Medal of Technology, the nation's highest recognition for technological achievement, "for extending and enhancing human life through innovative pharmaceutical research and development and for redefining the science of clinical study through groundbreaking and hugely complex clinical trials that are recognized models in the industry." In 2005, BMS was among 53 entities that contributed the maximum of $250,000 to the second inauguration of President George W. Bush.[3]
BMS is a Fortune 500 Company (#114 in 2010 list). Newsweek's 2009 Green Ranking recognized Bristol-Myers Squibb as 8th among 500 of the largest U.S. corporations. Also, BMS was included in the 2009 Dow Jones Sustainability North America Index of leading sustainability-driven companies.
In August 2009, BMS acquired the biotechnology firm Medarex as part of the company's "String of Pearls" strategy of alliances, partnerships and acquisitions.[4] In October 2010, the company acquired ZymoGenetics, securing an existing product as well as pipeline assets in hepatitis C, cancer and other therapeutic areas.
Bristol-Myers Squibb Company (BMS), incorporated in August 1933, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical products on a global basis. The Company’s products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in eight foreign countries. On October 12, 2010, the Company acquired ZymoGenetics, Inc. (ZymoGenetics).
The Company’s pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of and an increasing portion of products produced from biological processes called biologics. Small molecule drugs are typically administered orally in the form of a pill, although there are other drug delivery mechanisms that are used as well. Biologics are administered to patients through injections. The products include PLAVIX, AVAPRO/AVALIDE, ABILIFY, REYATAZ, SUSTIVA Franchise, BARACLUDE, ERBITUX, SPRYCEL, IXEMPRA, ORENCIA and ONGLYZA/KOMBIGLYZE.
PLAVIX (clopidogrel bisulfate) is a platelet aggregation inhibitor, which is approved for protection against fatal or non-fatal heart attack or stroke in patients with a history of heart attack, stroke, peripheral arterial disease or acute coronary syndrome. Clopidogrel bisulfate was co-developed and is jointly marketed with sanofi-aventis (sanofi). AVAPRO/AVALIDE (irbesartan/irbesartan-hydrochlorothiazide) is an angiotensin II receptor antagonist indicated for the treatment of hypertension and diabetic nephropathy. Irbesartan was co-developed and is jointly marketed with sanofi-aventis. Irbesartan is manufactured by both the Company and sanofi. The Company manufactures its bulk requirements for irbesartan and finish avapro/avalide in its facilities.
ABILIFY (aripiprazole) is an atypical antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder and major depressive disorder. ABILIFY also has pediatric uses in schizophrenia and bipolar disorder, among others. The Company obtains its bulk requirements for aripiprazole from Otsuka. The Company has a global commercialization agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka), except in Japan, China, Taiwan, North Korea, South Korea, the Philippines, Thailand, Indonesia, Pakistan and Egypt. Both the Company and Otsuka, finish the product in their own respective facilities. REYATAZ (atazanavir sulfate) is a protease inhibitor for the treatment of human immunodeficiency virus (HIV).
SUSTIVA (efavirenz) is a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV. The SUSTIVA Franchise includes SUSTIVA, an antiretroviral drug used in the treatment of HIV, and as well as bulk efavirenz, which is included in the combination therapy ATRIPLA (efavirenz 600 milligrams/emtricitabine 200 milligrams/tenofovir disoproxil fumarate 300 milligrams), a once-daily single tablet three-drug regimen combining its SUSTIVA and Gilead Sciences, Inc.’s (Gilead) TRUVADA (emtricitabine and tenofovir disoproxil fumarate). The Compay obtains its bulk requirements for efavirenz from third parties and produce finished goods in its facilities. The Company provides bulk efavirenz to Gilead Sciences, Inc.’s (Gilead), who is responsible for producing the finished ATRIPLA product.
ERBITUX (cetuximab) is an IgG1 monoclonal antibody designed to focus and block the epidermal growth factor receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types, as well as some normal cells. ERBITUX, a biological product, is approved for the treatment in combination with irinotecan for the treatment of patients with EGFR-expressing metastatic colorectal cancer (mCRC) who have failed an irinotecan-based regimen and as monotherapy for patients who are intolerant of irinotecan. The Food & Drug Administration (FDA) has also approved ERBITUX for use in the treatment of squamous cell carcinoma of the head and neck.
SPRYCEL (dasatinib) is a multi-targeted tyrosine kinase inhibitor approved for treatment of adults with all phases of chronic myeloid leukemia with resistance or intolerance to prior therapy, including GLEEVEC (imatinib mesylate), and for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. In 2010, the FDA approved SPRYCEL for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
IXEMPRA (ixabepilone) is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs. The Company manufactures its bulk requirements for ixabepilone in its facilities, including the manufacturing of the active ingredient. The drug product, which comprises a pharmaceutical kit, is finished by Baxter Oncology GmbH.
ORENCIA (abatacept), a biological product, is a fusion protein with immunosuppressive activity targeted initially at adult patients with moderate to severe rheumatoid arthritis, who have had an inadequate response to certain existing available treatments. ONGLYZA (saxagliptin), a dipeptidyl peptidase-4 inhibitor, is an oral compound indicated for the treatment of type II diabetes as an adjunct to diet and exercise. KOMBIGLYZE (saxagliptin and metformin) is a combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus when treatment with both saxagliptin and metformin is appropriate. Both ONGLYZA and KOMBIGLYZE were codeveloped by the Company and AstraZeneca PLC (AstraZeneca).
Bristol-Myers Squibb Company (BMS), incorporated in August 1933, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical products on a global basis. The Company’s products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in eight foreign countries. On October 12, 2010, the Company acquired ZymoGenetics, Inc. (ZymoGenetics).
The Company’s pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of and an increasing portion of products produced from biological processes called biologics. Small molecule drugs are typically administered orally in the form of a pill, although there are other drug delivery mechanisms that are used as well. Biologics are administered to patients through injections. The products include PLAVIX, AVAPRO/AVALIDE, ABILIFY, REYATAZ, SUSTIVA Franchise, BARACLUDE, ERBITUX, SPRYCEL, IXEMPRA, ORENCIA and ONGLYZA/KOMBIGLYZE.
PLAVIX (clopidogrel bisulfate) is a platelet aggregation inhibitor, which is approved for protection against fatal or non-fatal heart attack or stroke in patients with a history of heart attack, stroke, peripheral arterial disease or acute coronary syndrome. Clopidogrel bisulfate was co-developed and is jointly marketed with sanofi-aventis (sanofi). AVAPRO/AVALIDE (irbesartan/irbesartan-hydrochlorothiazide) is an angiotensin II receptor antagonist indicated for the treatment of hypertension and diabetic nephropathy. Irbesartan was co-developed and is jointly marketed with sanofi-aventis. Irbesartan is manufactured by both the Company and sanofi. The Company manufactures its bulk requirements for irbesartan and finish avapro/avalide in its facilities.
ABILIFY (aripiprazole) is an atypical antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder and major depressive disorder. ABILIFY also has pediatric uses in schizophrenia and bipolar disorder, among others. The Company obtains its bulk requirements for aripiprazole from Otsuka. The Company has a global commercialization agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka), except in Japan, China, Taiwan, North Korea, South Korea, the Philippines, Thailand, Indonesia, Pakistan and Egypt. Both the Company and Otsuka, finish the product in their own respective facilities. REYATAZ (atazanavir sulfate) is a protease inhibitor for the treatment of human immunodeficiency virus (HIV).
SUSTIVA (efavirenz) is a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV. The SUSTIVA Franchise includes SUSTIVA, an antiretroviral drug used in the treatment of HIV, and as well as bulk efavirenz, which is included in the combination therapy ATRIPLA (efavirenz 600 milligrams/emtricitabine 200 milligrams/tenofovir disoproxil fumarate 300 milligrams), a once-daily single tablet three-drug regimen combining its SUSTIVA and Gilead Sciences, Inc.’s (Gilead) TRUVADA (emtricitabine and tenofovir disoproxil fumarate). The Compay obtains its bulk requirements for efavirenz from third parties and produce finished goods in its facilities. The Company provides bulk efavirenz to Gilead Sciences, Inc.’s (Gilead), who is responsible for producing the finished ATRIPLA product.
ERBITUX (cetuximab) is an IgG1 monoclonal antibody designed to focus and block the epidermal growth factor receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types, as well as some normal cells. ERBITUX, a biological product, is approved for the treatment in combination with irinotecan for the treatment of patients with EGFR-expressing metastatic colorectal cancer (mCRC) who have failed an irinotecan-based regimen and as monotherapy for patients who are intolerant of irinotecan. The Food & Drug Administration (FDA) has also approved ERBITUX for use in the treatment of squamous cell carcinoma of the head and neck.
SPRYCEL (dasatinib) is a multi-targeted tyrosine kinase inhibitor approved for treatment of adults with all phases of chronic myeloid leukemia with resistance or intolerance to prior therapy, including GLEEVEC (imatinib mesylate), and for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. In 2010, the FDA approved SPRYCEL for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
IXEMPRA (ixabepilone) is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs. The Company manufactures its bulk requirements for ixabepilone in its facilities, including the manufacturing of the active ingredient. The drug product, which comprises a pharmaceutical kit, is finished by Baxter Oncology GmbH.
ORENCIA (abatacept), a biological product, is a fusion protein with immunosuppressive activity targeted initially at adult patients with moderate to severe rheumatoid arthritis, who have had an inadequate response to certain existing available treatments. ONGLYZA (saxagliptin), a dipeptidyl peptidase-4 inhibitor, is an oral compound indicated for the treatment of type II diabetes as an adjunct to diet and exercise. KOMBIGLYZE (saxagliptin and metformin) is a combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus when treatment with both saxagliptin and metformin is appropriate. Both ONGLYZA and KOMBIGLYZE were codeveloped by the Company and AstraZeneca PLC (AstraZeneca).
OVERALL
Beta: 0.62
Market Cap (Mil.): $47,938.28
Shares Outstanding (Mil.): 1,705.99
Annual Dividend: 1.32
Yield (%): 4.70
FINANCIALS
BMY.N Industry Sector
P/E (TTM): 14.49 25.14 40.56
EPS (TTM): 11.93 -- --
ROI: 19.53 6.46 1.92
ROE: 21.34 7.87 2.49
Statistics:
Public Company
Incorporated: 1900 as Bristol-Myers Company
Employees: 54,500
Sales: $20.22 billion (1999)
Stock Exchanges: New York
Ticker Symbol: BMY
NAIC: 325412 Pharmaceutical Preparations Manufacturing; 32562 Toilet Preparations Manufacturing
Key Dates:
1887: William McLaren Bristol and John Ripley Myers invest in the Clinton Pharmaceutical Company.
1900: The company changes its name to Bristol-Myers Company.
1915: Henry Bristol, William Bristol's oldest son, becomes general manager.
1928: The company becomes a part of Drug, Inc.; William Bristol Jr. and Lee Bristol become head of manufacturing and advertising, respectively.
1933: The holding company disbands.
1957: Henry Bristol becomes chair of the board; Fredric N. Schwartz becomes president and chief executive officer.
1959: Bristol-Myers acquires Clairol.
1967: Bristol-Myers acquires Mead Johnson.
1972: Richard Gelb is appointed chair and chief executive officer.
1983: The company introduces tamper-resistant packaging for its capsule products.
1984: Bristol-Myers builds a multimillion-dollar research facility in Wallingford, Connecticut.
1989: Bristol-Myers merges with Squibb Corporation; Gelb becomes chief executive.
1994: Major reorganization; worldwide revenues total $11.4 billion.
Address:
345 Park Avenue
New York, New York 10154-0037
U.S.A.
Lamberto Andreotti became the company's CEO on May 4, 2010. Former CEO James M. Cornelius remains chairman of the Board of Directors.
Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Its mission is to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases."
BMS' primary R&D sites are located in Princeton, New Jersey (formerly Squibb) and Wallingford, Connecticut (formerly Bristol-Myers), with other sites in Hopewell and New Brunswick, New Jersey, and in Braine-l'Alleud, Belgium, and Tokyo.
A major restructuring involves focusing on the pharmaceutical business and biologic products along with productivity initiatives and cost-cutting and streamlining business operations through a multi-year program of on-going layoffs. As another cost-cutting measure Bristol-Myers also reduced subsidies for health-care to retirees and plans to freeze their pension plan at the end of 2009.[citation needed]
In November 2009, Bristol-Myers Squibb announced that it was "splitting off" Mead Johnson Nutrition by offering BMY shareholders the opportunity to exchange their stock for shares in Mead Johnson. According to Bristol-Myers Squibb, this move is expected to further sharpen the company's focus on biopharmaceuticals.
In 1999, President Clinton awarded Bristol-Myers Squibb the National Medal of Technology, the nation's highest recognition for technological achievement, "for extending and enhancing human life through innovative pharmaceutical research and development and for redefining the science of clinical study through groundbreaking and hugely complex clinical trials that are recognized models in the industry." In 2005, BMS was among 53 entities that contributed the maximum of $250,000 to the second inauguration of President George W. Bush.[3]
BMS is a Fortune 500 Company (#114 in 2010 list). Newsweek's 2009 Green Ranking recognized Bristol-Myers Squibb as 8th among 500 of the largest U.S. corporations. Also, BMS was included in the 2009 Dow Jones Sustainability North America Index of leading sustainability-driven companies.
In August 2009, BMS acquired the biotechnology firm Medarex as part of the company's "String of Pearls" strategy of alliances, partnerships and acquisitions.[4] In October 2010, the company acquired ZymoGenetics, securing an existing product as well as pipeline assets in hepatitis C, cancer and other therapeutic areas.
Bristol-Myers Squibb Company (BMS), incorporated in August 1933, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical products on a global basis. The Company’s products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in eight foreign countries. On October 12, 2010, the Company acquired ZymoGenetics, Inc. (ZymoGenetics).
The Company’s pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of and an increasing portion of products produced from biological processes called biologics. Small molecule drugs are typically administered orally in the form of a pill, although there are other drug delivery mechanisms that are used as well. Biologics are administered to patients through injections. The products include PLAVIX, AVAPRO/AVALIDE, ABILIFY, REYATAZ, SUSTIVA Franchise, BARACLUDE, ERBITUX, SPRYCEL, IXEMPRA, ORENCIA and ONGLYZA/KOMBIGLYZE.
PLAVIX (clopidogrel bisulfate) is a platelet aggregation inhibitor, which is approved for protection against fatal or non-fatal heart attack or stroke in patients with a history of heart attack, stroke, peripheral arterial disease or acute coronary syndrome. Clopidogrel bisulfate was co-developed and is jointly marketed with sanofi-aventis (sanofi). AVAPRO/AVALIDE (irbesartan/irbesartan-hydrochlorothiazide) is an angiotensin II receptor antagonist indicated for the treatment of hypertension and diabetic nephropathy. Irbesartan was co-developed and is jointly marketed with sanofi-aventis. Irbesartan is manufactured by both the Company and sanofi. The Company manufactures its bulk requirements for irbesartan and finish avapro/avalide in its facilities.
ABILIFY (aripiprazole) is an atypical antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder and major depressive disorder. ABILIFY also has pediatric uses in schizophrenia and bipolar disorder, among others. The Company obtains its bulk requirements for aripiprazole from Otsuka. The Company has a global commercialization agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka), except in Japan, China, Taiwan, North Korea, South Korea, the Philippines, Thailand, Indonesia, Pakistan and Egypt. Both the Company and Otsuka, finish the product in their own respective facilities. REYATAZ (atazanavir sulfate) is a protease inhibitor for the treatment of human immunodeficiency virus (HIV).
SUSTIVA (efavirenz) is a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV. The SUSTIVA Franchise includes SUSTIVA, an antiretroviral drug used in the treatment of HIV, and as well as bulk efavirenz, which is included in the combination therapy ATRIPLA (efavirenz 600 milligrams/emtricitabine 200 milligrams/tenofovir disoproxil fumarate 300 milligrams), a once-daily single tablet three-drug regimen combining its SUSTIVA and Gilead Sciences, Inc.’s (Gilead) TRUVADA (emtricitabine and tenofovir disoproxil fumarate). The Compay obtains its bulk requirements for efavirenz from third parties and produce finished goods in its facilities. The Company provides bulk efavirenz to Gilead Sciences, Inc.’s (Gilead), who is responsible for producing the finished ATRIPLA product.
ERBITUX (cetuximab) is an IgG1 monoclonal antibody designed to focus and block the epidermal growth factor receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types, as well as some normal cells. ERBITUX, a biological product, is approved for the treatment in combination with irinotecan for the treatment of patients with EGFR-expressing metastatic colorectal cancer (mCRC) who have failed an irinotecan-based regimen and as monotherapy for patients who are intolerant of irinotecan. The Food & Drug Administration (FDA) has also approved ERBITUX for use in the treatment of squamous cell carcinoma of the head and neck.
SPRYCEL (dasatinib) is a multi-targeted tyrosine kinase inhibitor approved for treatment of adults with all phases of chronic myeloid leukemia with resistance or intolerance to prior therapy, including GLEEVEC (imatinib mesylate), and for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. In 2010, the FDA approved SPRYCEL for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
IXEMPRA (ixabepilone) is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs. The Company manufactures its bulk requirements for ixabepilone in its facilities, including the manufacturing of the active ingredient. The drug product, which comprises a pharmaceutical kit, is finished by Baxter Oncology GmbH.
ORENCIA (abatacept), a biological product, is a fusion protein with immunosuppressive activity targeted initially at adult patients with moderate to severe rheumatoid arthritis, who have had an inadequate response to certain existing available treatments. ONGLYZA (saxagliptin), a dipeptidyl peptidase-4 inhibitor, is an oral compound indicated for the treatment of type II diabetes as an adjunct to diet and exercise. KOMBIGLYZE (saxagliptin and metformin) is a combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus when treatment with both saxagliptin and metformin is appropriate. Both ONGLYZA and KOMBIGLYZE were codeveloped by the Company and AstraZeneca PLC (AstraZeneca).
Bristol-Myers Squibb Company (BMS), incorporated in August 1933, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical products on a global basis. The Company’s products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in eight foreign countries. On October 12, 2010, the Company acquired ZymoGenetics, Inc. (ZymoGenetics).
The Company’s pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of and an increasing portion of products produced from biological processes called biologics. Small molecule drugs are typically administered orally in the form of a pill, although there are other drug delivery mechanisms that are used as well. Biologics are administered to patients through injections. The products include PLAVIX, AVAPRO/AVALIDE, ABILIFY, REYATAZ, SUSTIVA Franchise, BARACLUDE, ERBITUX, SPRYCEL, IXEMPRA, ORENCIA and ONGLYZA/KOMBIGLYZE.
PLAVIX (clopidogrel bisulfate) is a platelet aggregation inhibitor, which is approved for protection against fatal or non-fatal heart attack or stroke in patients with a history of heart attack, stroke, peripheral arterial disease or acute coronary syndrome. Clopidogrel bisulfate was co-developed and is jointly marketed with sanofi-aventis (sanofi). AVAPRO/AVALIDE (irbesartan/irbesartan-hydrochlorothiazide) is an angiotensin II receptor antagonist indicated for the treatment of hypertension and diabetic nephropathy. Irbesartan was co-developed and is jointly marketed with sanofi-aventis. Irbesartan is manufactured by both the Company and sanofi. The Company manufactures its bulk requirements for irbesartan and finish avapro/avalide in its facilities.
ABILIFY (aripiprazole) is an atypical antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder and major depressive disorder. ABILIFY also has pediatric uses in schizophrenia and bipolar disorder, among others. The Company obtains its bulk requirements for aripiprazole from Otsuka. The Company has a global commercialization agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka), except in Japan, China, Taiwan, North Korea, South Korea, the Philippines, Thailand, Indonesia, Pakistan and Egypt. Both the Company and Otsuka, finish the product in their own respective facilities. REYATAZ (atazanavir sulfate) is a protease inhibitor for the treatment of human immunodeficiency virus (HIV).
SUSTIVA (efavirenz) is a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV. The SUSTIVA Franchise includes SUSTIVA, an antiretroviral drug used in the treatment of HIV, and as well as bulk efavirenz, which is included in the combination therapy ATRIPLA (efavirenz 600 milligrams/emtricitabine 200 milligrams/tenofovir disoproxil fumarate 300 milligrams), a once-daily single tablet three-drug regimen combining its SUSTIVA and Gilead Sciences, Inc.’s (Gilead) TRUVADA (emtricitabine and tenofovir disoproxil fumarate). The Compay obtains its bulk requirements for efavirenz from third parties and produce finished goods in its facilities. The Company provides bulk efavirenz to Gilead Sciences, Inc.’s (Gilead), who is responsible for producing the finished ATRIPLA product.
ERBITUX (cetuximab) is an IgG1 monoclonal antibody designed to focus and block the epidermal growth factor receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types, as well as some normal cells. ERBITUX, a biological product, is approved for the treatment in combination with irinotecan for the treatment of patients with EGFR-expressing metastatic colorectal cancer (mCRC) who have failed an irinotecan-based regimen and as monotherapy for patients who are intolerant of irinotecan. The Food & Drug Administration (FDA) has also approved ERBITUX for use in the treatment of squamous cell carcinoma of the head and neck.
SPRYCEL (dasatinib) is a multi-targeted tyrosine kinase inhibitor approved for treatment of adults with all phases of chronic myeloid leukemia with resistance or intolerance to prior therapy, including GLEEVEC (imatinib mesylate), and for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. In 2010, the FDA approved SPRYCEL for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
IXEMPRA (ixabepilone) is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs. The Company manufactures its bulk requirements for ixabepilone in its facilities, including the manufacturing of the active ingredient. The drug product, which comprises a pharmaceutical kit, is finished by Baxter Oncology GmbH.
ORENCIA (abatacept), a biological product, is a fusion protein with immunosuppressive activity targeted initially at adult patients with moderate to severe rheumatoid arthritis, who have had an inadequate response to certain existing available treatments. ONGLYZA (saxagliptin), a dipeptidyl peptidase-4 inhibitor, is an oral compound indicated for the treatment of type II diabetes as an adjunct to diet and exercise. KOMBIGLYZE (saxagliptin and metformin) is a combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus when treatment with both saxagliptin and metformin is appropriate. Both ONGLYZA and KOMBIGLYZE were codeveloped by the Company and AstraZeneca PLC (AstraZeneca).
OVERALL
Beta: 0.62
Market Cap (Mil.): $47,938.28
Shares Outstanding (Mil.): 1,705.99
Annual Dividend: 1.32
Yield (%): 4.70
FINANCIALS
BMY.N Industry Sector
P/E (TTM): 14.49 25.14 40.56
EPS (TTM): 11.93 -- --
ROI: 19.53 6.46 1.92
ROE: 21.34 7.87 2.49
Statistics:
Public Company
Incorporated: 1900 as Bristol-Myers Company
Employees: 54,500
Sales: $20.22 billion (1999)
Stock Exchanges: New York
Ticker Symbol: BMY
NAIC: 325412 Pharmaceutical Preparations Manufacturing; 32562 Toilet Preparations Manufacturing
Key Dates:
1887: William McLaren Bristol and John Ripley Myers invest in the Clinton Pharmaceutical Company.
1900: The company changes its name to Bristol-Myers Company.
1915: Henry Bristol, William Bristol's oldest son, becomes general manager.
1928: The company becomes a part of Drug, Inc.; William Bristol Jr. and Lee Bristol become head of manufacturing and advertising, respectively.
1933: The holding company disbands.
1957: Henry Bristol becomes chair of the board; Fredric N. Schwartz becomes president and chief executive officer.
1959: Bristol-Myers acquires Clairol.
1967: Bristol-Myers acquires Mead Johnson.
1972: Richard Gelb is appointed chair and chief executive officer.
1983: The company introduces tamper-resistant packaging for its capsule products.
1984: Bristol-Myers builds a multimillion-dollar research facility in Wallingford, Connecticut.
1989: Bristol-Myers merges with Squibb Corporation; Gelb becomes chief executive.
1994: Major reorganization; worldwide revenues total $11.4 billion.
Address:
345 Park Avenue
New York, New York 10154-0037
U.S.A.
Last edited: